Evidence map›Paper›PMID 40337848›Full record

ArticleFuture medicinal chemistry2025

Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors.

Ibrahim H Eissa, Hazem Elkady, Walid E Elgammal, Hazem A Mahdy, Hany S Elshennawy, Dalal Z Husein, Fatma G Amin, Ibrahim M Ibrahim, Bshra A Alsfouk, Eslam B Elkaeed and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Dual-target carbonic anhydrase inhibitors in cancer therapy: progress, challenges, and opportunities.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Common Food Additives Inhibit Carbonic Anhydrase Activity.Journal of biochemical and molecular toxicology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ibrahim H EissaPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Hazem ElkadyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Walid E ElgammalDepartment of Chemistry, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Hazem A MahdyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Hany S ElshennawyFaculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
Dalal Z HuseinChemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
Fatma G AminPhysics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Ibrahim M IbrahimBiophysics Department, Faculty of Science, Cairo University, Giza, Egypt.
Bshra A AlsfoukDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Eslam B ElkaeedDepartment of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.
Ahmed M MetwalyPharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThiadiazole-sulfonamide derivatives were synthesized as dual inhibitors of epidermal growth factor receptor (EGFR) and carbonic anhydrase IX (CA-IX) to develop selective anticancer agents.

methodsCytotoxicity was evaluated against MDA-MB-231 and MCF-7 breast cancer cells, with selectivity tested on Vero cells. Enzymatic inhibition studies were conducted against EGFR and CA-IX, using erlotinib and acetazolamide as reference drugs. Apoptosis was assessed through gene expression analysis of BAX/Bcl-2, caspase-8, and caspase-9, alongside flow cytometry for apoptosis and cell cycle analysis. Molecular docking and 200 ns molecular dynamics (MD) simulations evaluated binding interactions. Density Functional Theory (DFT) calculations and

resultsCompound

conclusionsCompound

Indexed as

Antineoplastic AgentsCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXErbB ReceptorsSulfonamidesThiadiazolesAnimalsAntigens, NeoplasmApoptosisCell Line, TumorCell ProliferationChlorocebus aethiopsDrug Screening Assays, AntitumorHumansMCF-7 CellsMolecular Docking SimulationAntigens, NeoplasmAntineoplastic AgentsCA9 protein, humanCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXEGFR protein, humanErbB ReceptorsSulfonamidesThiadiazolesAnti-cancerapoptosis, computational studiesdrug designdual EGFR-carbonic anhydrase inhibitorsthiadiazole-sulfonamide

Identifiers

PMID40337848
PMCPMC12091935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.